Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

Sponsors and Collaborators
H. Lee Moffitt Cancer Center and Research Institute

Continue Reading

Millennium Pharmaceuticals, Inc.

Contact
Nathalie Luis, BS

813-745-6040

[email protected] 

Principal Investigators
Melissa Alsina, MD
H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier
NCT00948922